Maria Rappai, MD
Pulmonary Disease · Jackson, MSNPI 1972597961
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Intuitive Surgical at 56.1% of the total.
Across 438 payments — averaging $45.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- GSK$4K
- Inspire Medical Systems, Inc.$1K
- Abiomed$589
- Actelion Pharmaceuticals US, Inc.$566
- Insmed, Inc.$505
- plus $2K from 20 others
Across 37 payments — averaging $682.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$25K
What the payments were for
- Travel & lodging$8,73844%
- Food & beverage$8,96145%
- Education$2,09911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 52 | $11,112 |
| GSK | 229 | $3,760 |
| Inspire Medical Systems, Inc. | 11 | $1,219 |
| Abiomed | 13 | $589 |
| Actelion Pharmaceuticals US, Inc. | 18 | $566 |
| Insmed, Inc. | 36 | $505 |
| Sanofi | 3 | $246 |
| AstraZeneca | 10 | $242 |
| Merck | 6 | $219 |
| Jazz Pharmaceuticals Inc. | 8 | $170 |
| Johnson & Johnson | 9 | $138 |
| Ceribell, Inc. | 1 | $132 |
| United Therapeutics Corporation | 1 | $117 |
| Pfizer | 6 | $112 |
| Siemens Medical Solutions USA, Inc. | 1 | $103 |
| E.r. Squibb & Sons, L.L.C. | 7 | $98 |
| Gilead | 5 | $86 |
| Novartis | 5 | $71 |
| Boehringer Ingelheim | 4 | $69 |
| Mallinckrodt Hospital Products Inc. | 3 | $65 |
| Inari Medical, Inc. | 4 | $64 |
| Genentech USA, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Covidien LP | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,798 in reported general payments places this provider in the 85th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 30 | $746,037 |
| UptraviSelexipag | 38 | $714,553 |
| OfevNintedanib Esylate | 53 | $642,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 453 | $344,077 |
| Ambrisentan | 51 | $332,232 |
| Breo ElliptaFluticasone/Vilanterol | 210 | $94,706 |
| NucalaMepolizumab | 24 | $90,294 |
| Dupixent PenDupilumab | 16 | $80,006 |
| AdempasRiociguat | 14 | $74,815 |
| Fasenra PenBenralizumab | 11 | $69,755 |
| EliquisApixaban | 98 | $67,056 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $66,901 |
| XareltoRivaroxaban | 94 | $65,613 |
| Dupixent SyringeDupilumab | 15 | $54,902 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $44,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $566 | $714,55338 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $69 | $666,98597 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $3,760 | $584,563798 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $242 | $94,347192 claims |
| PfizerEliquis | $112 | $67,05698 claims |
| Johnson & JohnsonXarelto | $138 | $65,61394 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- George AbrahamJackson$23K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
- Meredith SloanJackson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.